[Use of pronoran (piribedil) in Parkinson's disease: the results of a multicenter study].
Identifieur interne : 003053 ( Main/Exploration ); précédent : 003052; suivant : 003054[Use of pronoran (piribedil) in Parkinson's disease: the results of a multicenter study].
Auteurs : N V FedorovaSource :
- Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova [ 1997-7298 ] ; 2003.
English descriptors
- KwdEn :
- Antiparkinson Agents (administration & dosage), Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Dopamine Agents (administration & dosage), Dopamine Agents (therapeutic use), Dopamine Agonists (administration & dosage), Dopamine Agonists (adverse effects), Dopamine Agonists (therapeutic use), Drug Therapy, Combination, Humans, Levodopa (administration & dosage), Levodopa (therapeutic use), Parkinson Disease (drug therapy), Piribedil (administration & dosage), Piribedil (adverse effects), Piribedil (therapeutic use), Placebos, Time Factors, Treatment Outcome.
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Dopamine Agents, Dopamine Agonists, Levodopa, Piribedil.
- chemical , adverse effects : Antiparkinson Agents, Dopamine Agonists, Piribedil.
- chemical , therapeutic use : Antiparkinson Agents, Dopamine Agents, Dopamine Agonists, Levodopa, Piribedil.
- drug therapy : Parkinson Disease.
- Drug Therapy, Combination, Humans, Placebos, Time Factors, Treatment Outcome.
Abstract
The study of 99 patients has been conducted in 5 Russian centers. Pronoran ("Servier", France) combined with levodopa was used in dosage 50-150 mg daily during 6 months. The treatment was placebo-controlled. Significant differences (p < 0.001) between the study and control groups in expression of all main symptoms of the disease were found.
PubMed: 14681961
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001146
- to stream PubMed, to step Curation: 001105
- to stream PubMed, to step Checkpoint: 001105
- to stream Ncbi, to step Merge: 000406
- to stream Ncbi, to step Curation: 000406
- to stream Ncbi, to step Checkpoint: 000406
- to stream Main, to step Merge: 003486
- to stream Main, to step Curation: 003053
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Use of pronoran (piribedil) in Parkinson's disease: the results of a multicenter study].</title>
<author><name sortKey="Fedorova, N V" sort="Fedorova, N V" uniqKey="Fedorova N" first="N V" last="Fedorova">N V Fedorova</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2003">2003</date>
<idno type="RBID">pubmed:14681961</idno>
<idno type="pmid">14681961</idno>
<idno type="wicri:Area/PubMed/Corpus">001146</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001146</idno>
<idno type="wicri:Area/PubMed/Curation">001105</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001105</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001105</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001105</idno>
<idno type="wicri:Area/Ncbi/Merge">000406</idno>
<idno type="wicri:Area/Ncbi/Curation">000406</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000406</idno>
<idno type="wicri:doubleKey">1997-7298:2003:Fedorova N:use:of:pronoran</idno>
<idno type="wicri:Area/Main/Merge">003486</idno>
<idno type="wicri:Area/Main/Curation">003053</idno>
<idno type="wicri:Area/Main/Exploration">003053</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">[Use of pronoran (piribedil) in Parkinson's disease: the results of a multicenter study].</title>
<author><name sortKey="Fedorova, N V" sort="Fedorova, N V" uniqKey="Fedorova N" first="N V" last="Fedorova">N V Fedorova</name>
</author>
</analytic>
<series><title level="j">Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova</title>
<idno type="ISSN">1997-7298</idno>
<imprint><date when="2003" type="published">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (administration & dosage)</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Dopamine Agents (administration & dosage)</term>
<term>Dopamine Agents (therapeutic use)</term>
<term>Dopamine Agonists (administration & dosage)</term>
<term>Dopamine Agonists (adverse effects)</term>
<term>Dopamine Agonists (therapeutic use)</term>
<term>Drug Therapy, Combination</term>
<term>Humans</term>
<term>Levodopa (administration & dosage)</term>
<term>Levodopa (therapeutic use)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Piribedil (administration & dosage)</term>
<term>Piribedil (adverse effects)</term>
<term>Piribedil (therapeutic use)</term>
<term>Placebos</term>
<term>Time Factors</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Dopamine Agents</term>
<term>Dopamine Agonists</term>
<term>Levodopa</term>
<term>Piribedil</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Dopamine Agonists</term>
<term>Piribedil</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Dopamine Agents</term>
<term>Dopamine Agonists</term>
<term>Levodopa</term>
<term>Piribedil</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Drug Therapy, Combination</term>
<term>Humans</term>
<term>Placebos</term>
<term>Time Factors</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The study of 99 patients has been conducted in 5 Russian centers. Pronoran ("Servier", France) combined with levodopa was used in dosage 50-150 mg daily during 6 months. The treatment was placebo-controlled. Significant differences (p < 0.001) between the study and control groups in expression of all main symptoms of the disease were found.</div>
</front>
</TEI>
<affiliations><list></list>
<tree><noCountry><name sortKey="Fedorova, N V" sort="Fedorova, N V" uniqKey="Fedorova N" first="N V" last="Fedorova">N V Fedorova</name>
</noCountry>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003053 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003053 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:14681961 |texte= [Use of pronoran (piribedil) in Parkinson's disease: the results of a multicenter study]. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:14681961" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a ParkinsonFranceV1
![]() | This area was generated with Dilib version V0.6.29. | ![]() |